Medication

Lipid-lowering medications

11-06-2018 | Cardiovascular outcomes | Highlight | News

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

Source:: Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30290-0
Lancet Diabetes Endocrinol 2018; doi:10.1016/S2213-8587(18)30311-5

10-26-2018 | PCSK9 inhibitors | Review | Article

Inhibiting PCSK9: Biology beyond LDL control

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

10-15-2018 | Statins | Review | Article

Beyond statins: Who and when to prescribe?

Ganda O. Curr Diab Rep 2018; 18: 126. doi: 10.1007/s11892-018-1087-0

09-24-2018 | Atherosclerosis | Article

Prevention of atherothrombotic events in patients with diabetes mellitus: From antithrombotic therapies to new-generation glucose-lowering drugs

Patti G et al. Nat Rev Cardiol 2018. doi: 10.1038/s41569-018-0080-2

06-30-2018 | Metformin | Review | Article

Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy

van Stee MF, de Graaf AA, Groen AK. Cardiovasc Diabetol 2018; 17: 94. doi: 10.1186/s12933-018-0738-4

06-25-2018 | Cardiovascular disorders | Review | Article

Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment

Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5

06-08-2018 | Cardiovascular outcomes | Article

Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: A 7-year follow-up study

Blanc-Bisson C et al. Cardiovasc Diabetol 2018; 17: 82. doi: 10.1186/s12933-018-0718-8

05-28-2018 | Lifestyle interventions | Case report | Article

Successful management of poorly controlled type 2 diabetes with multidisciplinary neurobehavioral rehabilitation: A case report and review

Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7

05-22-2018 | Cardiovascular disorders | Article

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes

Matsutani D et al. Cardiovasc Diabetol 2018; 17: 73. doi: 10.1186/s12933-018-0717-9

05-19-2018 | Risk factors | Review | Article

Prioritising risk factors for type 2 diabetes: Causal inference through genetic approaches

Wittemans LBL, Lotta LA, Langenberg C. Curr Diab Rep 2018; 18: 40. doi: 10.1007/s11892-018-1009-1

05-15-2018 | Type 2 diabetes | Article

Prevalence and incidence of complications at diagnosis of T2DM and during follow-up by BMI and ethnicity: A matched case–control analysis

Owusu Adjah ES et al. Cardiovasc Diabetol 2018; 17: 70. doi: 10.1186/s12933-018-0712-1

05-23-2018 | PCSK9 inhibitors | Article

Efficacy and safety of alirocumab in individuals with diabetes mellitus: Pooled analyses from five placebo-controlled phase 3 studies

Ginsberg HN et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0439-8

05-08-2018 | Cardiovascular disorders | Article

Sex-specific relevance of diabetes to occlusive vascular and other mortality: A collaborative meta-analysis of individual data from 980,793 adults from 68 prospective studies

Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration. Lancet Diabetes Endocrinol 2018; Advance online publication. doi: 10.1016/S2213-8587(18)30079-2

04-25-2018 | Lipid-lowering medications | Article

Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: Systemic assessment of pharmacological and nutritional factors

Gant CM et al. Nutr Diabetes 2018; 8: 24. doi: 10.1038/s41387-018-0028-y

04-06-2018 | Statins | Article

Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: Report of a randomized study

Itho H et al. Diabetes Care 2018; Advance online publication. doi: 10.2337/dc17-2224

03-01-2018 | Lipid-lowering medications | News

Fenofibrate produces large gout risk reduction in diabetes patients

The anti-cholesterol medication fenofibrate significantly reduces uric acid levels and more than halves the risk for gout in patients with type 2 diabetes, shows an analysis of the FIELD cohort.

Source:: Lancet Diabetes Endocrinol 2018; Advance online publication

01-05-2018 | Cardiovascular outcomes | Review | Article

Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: Established and emerging agents

Saxon DR, Rasouli N, Eckel RH. Drugs 2018; 78: 203–214. doi: 10.1007/s40265-017-0857-3

12-19-2017 | Cardiovascular disorders | Review | Article

New treatment options for lipid-lowering therapy in subjects with type 2 diabetes

Scicali R et al. Acta Diabetol 2017; 55: 209–218. doi: 10.1007/s00592-017-1089-4

11-01-2017 | Adolescents | News

No renal benefits of ACE inhibitor, statin treatment in adolescents with type 1 diabetes

Results of AdDIT show that treatment with an ACE inhibitor, a statin, or both does not protect against the increased albumin excretion that frequently occurs in patients with type 1 diabetes during adolescence.

Source:: N Engl J Med 2017; 377: 1733–1745

09-18-2017 | PCSK9 inhibitors | EASD 2017 | News

FOURIER: Evolocumab cardiovascular benefits extend to diabetes patients

A prespecified analysis of the FOURIER trial shows that the PCSK9 inhibitor evolocumab is as beneficial in patients with diabetes as in those without.

Source:: Lancet Diabetes Endocrinol 2017; Advance online publication

image credits

Heartbeat/© BrianAJackson / Getty Images /, Smiling doctors/© neringafoto/Getty Images/iStock, Diverse group holding 'diabetes'/© Rawpixel/Getty Images/iStock

Medicine Matters Diabetes